0001104659-24-030174.txt : 20240301 0001104659-24-030174.hdr.sgml : 20240301 20240301215246 ACCESSION NUMBER: 0001104659-24-030174 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240222 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pla Frederic CENTRAL INDEX KEY: 0001649167 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40344 FILM NUMBER: 24712709 MAIL ADDRESS: STREET 1: C/O GENOMIC HEALTH, INC. STREET 2: 101 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063-4700 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akoya Biosciences, Inc. CENTRAL INDEX KEY: 0001711933 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 475586242 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 BUSINESS PHONE: 855.896.8401 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE STREET 2: 6TH FLOOR CITY: MARLBOROUGH STATE: MA ZIP: 01762 4 1 tm247817-4_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-02-22 0 0001711933 Akoya Biosciences, Inc. AKYA 0001649167 Pla Frederic 100 CAMPUS DRIVE, 6TH FLOOR MARLBOROUGH MA 01752 0 1 0 0 Chief Operating Officer 0 Common Stock 2024-02-22 4 A 0 35000 0.00 A 105555 D Common Stock 2024-03-01 4 F 0 2049 6.03 D 103506 D Common Stock 20000 I By The Pla Family Trust dtd 8/7/14 Employee Stock Option (Right to Buy) 5.35 2024-02-22 4 A 0 70000 0.00 A 2034-02-22 Common Stock 70000 70000 D The restricted stock units shall vest in four (4) equal annual installments beginning on March 1, 2025, and annually thereafter until fully vested. Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock. Represents shares withheld to cover taxes on a restricted stock unit award previously granted February 23, 2023, which vest in four (4) equal annual installments beginning on March 1, 2024, and annually thereafter until fully vested. The options shall vest as follows: twenty-five percent (25%) shall vest on February 22, 2025 with the remainder vesting in 36 equal monthly installments beginning on March 22, 2025. /s/ Frederic Pla, by Brian McKelligon, as Attorney-in-Fact 2024-03-01